AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03517241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual testing
Description: Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
Study NCT01967004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morph
Description: Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
Study NCT03335319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized Exercise Training Regime
Description: MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or > 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
Study NCT03335319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Periodized Exercise Training Regime
Description: To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
Study NCT03824717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dose of ropivacaine
Description: Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
Study NCT02820870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Statin Decision Support Intervention
Description: The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline.
Study NCT02829047 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vibrating Capsule
Description: Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
Study NCT03545932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program hydrogymnastics
Description: 4 months of practice hydrogymnastics
Study NCT02487537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: custom-made soft drink
Study NCT02487537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: custom-made soft drink
Study NCT04061278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy
Description: 4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
Study NCT04061278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy
Description: 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
Study NCT01152996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study NCT01042821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial rectal wall advancement flap
Description: The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
Study NCT01042821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucosal advancement flap
Description: Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
Study NCT03668665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ready Medical Post Treatment
Description: Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed
Study NCT03668665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionell Treatment
Description: Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
Study NCT00827515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
Study NCT00827515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
Study NCT00827515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
Study NCT00827515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
Study NCT01247350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study NCT01247350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03169907 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mid trimesteric fetal ultrasonography
Description: Venous and arterial Doppler indices:~1. Middle cerebral artery (MCA) peak systolic velocity (PSV):~2. Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~3. Ductus venosus (DV) Doppler:~Cardiac functions:~1. Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~2. Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~3. Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)
Study NCT02895685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dyad training
Description: Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
Study NCT01266824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride Ophthalmic Solution
Description: 1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
Study NCT00576862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
Study NCT00653367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve section
Description: Intercostal nerve is divided during surgery
Study NCT02921945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT800
Description: recombinant human coagulation factor VIII
Study NCT02477878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501
Description: Biological: T cells transduced with CaspaCIDe suicide gene
Study NCT01535027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide 20 ug/day, sc.
Study NCT01535027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide and raloxifene
Description: teriparatide 20 ug/day sc. raloxifene 60mg oral daily
Study NCT01535027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide and alendronate
Description: teriparatide 20 ug/day sc. alendronate 70mg oral weekly
Study NCT02477878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid administered to treat GVHD
Study NCT04263987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moses laser enucleation of prostate
Description: Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time
Study NCT04263987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moses laser enucleation of prostate
Description: Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time
Study NCT00561145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction period
Description: The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
Study NCT02335255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine Hydrochloride Gel 2%
Description: Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Study NCT02335255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® Gel 2%
Description: Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Study NCT02335255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Study NCT03273920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic distal gastrectomy with D2 nodal dissection
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study NCT03273920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic distal gastrectomy with D2 nodal dissection
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT01004978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin-Eluting Beads
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin-Eluting Beads
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01004978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01004978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01004978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Undergo TACE
Study NCT01004978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01004978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01004978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT01004978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT03197662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (IN-OXT)
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Study NCT03197662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Study NCT02752360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Stenting Anastomoses
Description: Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
Study NCT02752360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-layer Hand Sutures
Description: Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
Study NCT01575756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octafibrin
Description: Octafibrin was supplied as a powder for reconstitution with water for injection.
Study NCT01575756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemocomplettan® P or RiaSTAPTM
Description: Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
Study NCT00508911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008
Description: GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
Study NCT00508911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COC
Description: COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
Study NCT00527280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feasibility ot face transplantation
Description: Feasibility ot face transplantation
Study NCT01438112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070 Adenovirus Vector
Description: CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
Study NCT01438112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm: Quadruple Choice
Description: Quadruple Choice Treatment Options: (same as listed above)
Study NCT04024605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
Study NCT04024605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapeseed
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
Study NCT04024605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
Study NCT04024605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lupin
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotores Training
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver training
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed caregiver training
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Materials support
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed materials support
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical assistance
Study NCT00594880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha 2a, 180 mcg/week sc
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Study NCT02534597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed technical assistance
Study NCT01749410 — intervention group
Intervention type: BIOLOGICAL
Intervention: onabotulinumtoxinA
Description: Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Study NCT04194983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oils and dairy fat
Description: 12-weeks, 3x per day